Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Beattie

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Medicinal Chemistry|December 19, 2019
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-<i>a</i>]pyridin-6-yl)amino]-9-(tetrahydro-2<i>H</i>-pyran-4-yl)-7,9-dihydro-8<i>H</i>-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) InhibitorFrederick W Goldberg, M Raymond V Finlay, Attilla K T Ting, et al.
ACS Medicinal Chemistry Letters|August 18, 2022
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8<i>H</i>-purin-8-one Inhibitors of DNA-PKFrederick W Goldberg, Attilla K T Ting, David Beattie, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2014
The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonistNicola Arnold, David Beattie, Michelle Bradley, et al.
Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.
Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Journal of Medicinal Chemistry|January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate CancerJames S Scott, Laura Evans, Peter C Astles, et al.
Bioorganic & Medicinal Chemistry|September 8, 2004
Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate estersDavid A Sandham, Lucy Barker, David Beattie, et al.
Journal of Medicinal Chemistry|April 21, 2010
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonistFrançois Baur, David Beattie, David Beer, et al.
Journal of Medicinal Chemistry|July 31, 2024
Discovery and <i>In Vivo</i> Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA CooperativityJames M Smith, Bernard Barlaam, David Beattie, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Medicinal Chemistry|December 19, 2019
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-<i>a</i>]pyridin-6-yl)amino]-9-(tetrahydro-2<i>H</i>-pyran-4-yl)-7,9-dihydro-8<i>H</i>-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) InhibitorFrederick W Goldberg, M Raymond V Finlay, Attilla K T Ting, et al.
ACS Medicinal Chemistry Letters|August 18, 2022
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8<i>H</i>-purin-8-one Inhibitors of DNA-PKFrederick W Goldberg, Attilla K T Ting, David Beattie, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2014
The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonistNicola Arnold, David Beattie, Michelle Bradley, et al.
Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.
Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Journal of Medicinal Chemistry|January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate CancerJames S Scott, Laura Evans, Peter C Astles, et al.
Bioorganic & Medicinal Chemistry|September 8, 2004
Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate estersDavid A Sandham, Lucy Barker, David Beattie, et al.
Journal of Medicinal Chemistry|April 21, 2010
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonistFrançois Baur, David Beattie, David Beer, et al.
Journal of Medicinal Chemistry|July 31, 2024
Discovery and <i>In Vivo</i> Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA CooperativityJames M Smith, Bernard Barlaam, David Beattie, et al.
Pageof 3